eli lilly lawsuit tirzepatide update today FDA approves tirzepatide, Lilly's new type 2 diabetes drug, and the company shares an estimated price Novo Nordisk sues Lilly over

Administration: Royal Booster Injection must be administered by a licensed healthcare professional a doctor, nurse, or qualified aesthetician in a clinical setting

On timing: once your prescriber submits the PA with complete documentation, standard decisions typically come back within days to two weeks, and your prescriber can request an expedited review when a treatment gap poses risk

Insurers role Health insurers are also noticing GLP-1 utilization rise

These numbers explain why tirzepatide has generated extraordinary demand and why the dosing protocols follow such a careful titration schedule: you start at 2.5 mg weekly for four weeks, increase to 5 mg, then continue stepping up through 7.5 mg, 10 mg, 12.5 mg, and potentially 15 mg depending on clinical response and tolerability